Author: Bridge Therapeutics

9th July 2024

A small study showed that nearly 90% of patients rotated to tiny doses of buprenorphine had the same pain relief as usual (full agonist) opioids, though at 1/60th the opioid milligram equivalent (OME). This study will help patients switch from full-agonist opioids to the much safer partial-agonist opioid buprenorphine.

8th May 2024

Bridge is pleased to announce our engagement with US Capital Global Securities for a $50 million equity offering. We are excited to offer eligible investors a unique opportunity to participate in this equity offering. USCG’s expertise in facilitating growth-stage investments makes them an ideal partner for this endeavor.

26th March 2024

Just a few years ago, only a small percentage of jails were providing MOUD to the general population with OUD. Today, about 30% of jails provide buprenorphine and about 20% of jails provide methadone, two of the three FDA-approved MOUDs. Agonist medications— methadone and buprenorphine—have the strongest evidence supporting their use.

1st November 2023

The CDC’s 2016 opioid guideline recommended that daily opioid doses not exceed 90 morphine milligram equivalents (MME). Although voluntary, the guideline was seized upon by other federal agencies and state legislatures to justify draconian new laws and regulations that limited opioid doses to 90 MME or less. No such limits have been set for buprenorphine. However, few doctors in the U.S. prescribe buprenorphine for pain, despite recent studies demonstrating its efficacy and international recognition that it is an effective analgesic.

18th September 2023

NIH-funded study suggests need to reevaluate opioid addiction treatment recommendations in the era of fentanyl. These findings build upon accumulating evidence of the safety and efficacy of higher doses of buprenorphine. Studies have shown that more than 16 mg of buprenorphine is safe and well tolerated in people with opioid use disorder in emergency department and outpatient treatment settings.

30th March 2023

Results from a multi-site clinical trial supported by the National Institutes of Health showed that less than 1% of people with opioid use disorder whose drug use includes fentanyl experienced withdrawal when starting buprenorphine in the emergency department. The findings, which appeared today in JAMA Network Open, are strong evidence that buprenorphine, a medication approved…

25th February 2023

Prince who’s one of the most well-known addiction recovery and mental health advocates is one of several super-successful entrepreneurs featured in the book. Prince talks about the art of relationship building while being mindful of your mental health even at the height of success. He should know coming up on 15 years sober in July…

3rd February 2023

Partnerships have become crucial in helping people transition out of correction facilities with SUD treatment. For example, substance use disorder provider Groups Recover Together has partnered with several state correctional departments, including Indiana and Maine’s department of corrections (DOC), to provide transitional care and reentry services for individuals transitioning out of incarceration.

17th January 2023

Bridge Therapeutics, today said that the MAT Act removes the outdated registration requirements on buprenorphine, making it possible for providers nationwide to prescribe it as they would any other controlled medication. Buprenorphine is a partial agonist or partial-acting opioid that treats addiction and chronic pain more safely than full-agonist opioids like morphine, oxycodone and fentanyl.

5th January 2023

Treatment for opioid use disorder is limited by there not being enough people that offer medications for opioid use disorder,” said Brian Hurley, MD, MBA, president-elect of the American Society of Addiction Medicine (ASAM). “Removal of the X waiver opens up the capability of prescribing to a much broader group of clinicians.